Company overview
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing AGIO with another company.
| Daily close (USD) | $31.92 |
| Market capitalization (USD) | $1,905,684,073.44 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.86 |
No matching rows. Clear the filter to see all records.
Read AGIO's valuation metrics
Company size
Agios Pharmaceuticals, Inc.'s recorded market capitalization is $1,905,684,073.44. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
AGIO's recorded price-to-book ratio is 1.86. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Agios Pharmaceuticals, Inc. with Aurora
Use the snapshot above to ask a specific question about AGIO. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow AGIO's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.